Comparing Revenue Performance: United Therapeutics Corporation or Lantheus Holdings, Inc.?

United Therapeutics vs. Lantheus: A Decade of Revenue Growth

__timestampLantheus Holdings, Inc.United Therapeutics Corporation
Wednesday, January 1, 20143016000001288519000
Thursday, January 1, 20152934610001465761000
Friday, January 1, 20163018530001598800000
Sunday, January 1, 20173313780001725300000
Monday, January 1, 20183433740001627800000
Tuesday, January 1, 20193473370001448800000
Wednesday, January 1, 20203394100001483300000
Friday, January 1, 20214252080001685500000
Saturday, January 1, 20229350610001936300000
Sunday, January 1, 202312964290002327500000
Loading chart...

Cracking the code

Revenue Growth: United Therapeutics vs. Lantheus Holdings

In the competitive landscape of the pharmaceutical industry, revenue performance is a key indicator of success. Over the past decade, United Therapeutics Corporation and Lantheus Holdings, Inc. have shown remarkable growth trajectories. From 2014 to 2023, United Therapeutics consistently outperformed Lantheus Holdings, with revenues peaking at approximately $2.3 billion in 2023, marking an 80% increase from 2014. Meanwhile, Lantheus Holdings experienced a significant surge, especially in recent years, with a 330% increase, reaching around $1.3 billion in 2023. This growth reflects strategic advancements and market expansions. The data highlights a pivotal moment in 2022 when Lantheus Holdings' revenue nearly doubled, indicating a potential shift in market dynamics. As these companies continue to innovate, their revenue trends offer valuable insights into their competitive strategies and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025